Second-degree heart block or complete heart block (CHB) is a relatively frequent complication of acute inferior wall myocardial infarction (AIWMI). This study investigated whether the PercuSurge device can prevent procedure-related CHB or can shorten CHB recovery time in patients with AIWMI undergoing primary percutaneous coronary intervention (PCI). Between May 2002 and April 2005, a PercuSurge device was utilized in 113 patients (study population, group 1) with AIWMI due to obstruction of the right coronary artery (RCA) with a reference lumen diameter (RLD) ≥ 3.5 mm.
SECOND-degree heart block or complete heart block (CHB) is a relatively frequent complication of acute myocardial infarction (AMI), with an incidence as high as 20% for patients with acute inferior wall MI (AIWMI). [1] [2] [3] [4] Patients with CHB are significantly more likely to die during hospitalization than patients without CHB. [4] [5] [6] [7] [8] [9] The duration of CHB varies dramatically from a few minutes to more than 10 days and permanent pacemaker implantation is very seldom required. 4, 10) Additionally, the duration of hospitalization is significantly longer for patients with CHB than those patients without CHB. 11) Furthermore, temporary pacemaker implantation for CHB increases the duration of being bedridden and the likelihood of infection, increasing patient suffering, especially for elderly patients with degenerative spine or spinal lesions. The exact mechanism causing CHB in patients with AIWMI remains uncertain. 8) However, atrioventricular nodal artery ischemia, Bezold-Jarisch reflex, and chemical mediators have been proposed as causes of CHB. 4) The PercuSurge device recently emerged as an attractive mechanical device that effectively restores normal coronary blood flow in the infarct-related artery (IRA), preventing both embolization in microvasculature and no reflow, particularly in patients with high-burden thrombus formation (HBTF) in the IRA. 12, 13) To the best of our knowledge, no data addressing the impact of the PercuSurge device on additional benefits in reducing a new onset of CHB following primary percutaneous coronary intervention (PCI) or on shortening the recovery time of CHB which developed after AIWM exists.
METHODS

Enrollment and exclusion criteria:
The enrollment for this study has been described in detail in our recently published study. 12) Enrollment criteria were as follows: 1) angiographic morphologic features of an IRA containing HBTF (the definition is described in detail in our recently published study); 14) and, 2) an AIWMI not more than 12 hours earlier. Exclusion criteria were as follows: 1) reference lumen diameter of the IRA < 3.5 mm; 2) a heavily calcified IRA; and, 3) a very tortuous IRA. reference lumen diameter of the IRA ≥ 3.5 mm and HBTF served as control subjects (group 2). The study protocol was approved by the Institutional Review Committee on Human Research of our institution. Procedure and protocol: A transradial approach using a 6-F arterial sheath has been the design protocol for AMI at our hospital since 2001. When diagnostic results demonstrated that the IRA met the criteria for PercuSurge device therapy, the 6-F arterial sheath was then replaced with a 7-F arterial sheath and a 7-F standard interventional guiding catheter was selectively positioned in the culprit artery. Thrombectomy with an Export Suction Catheter was performed prior to coronary angioplasty. Femoral vein puncture and temporary pacemaker implantation were required when CHB was identified in the catheterization laboratory. Definitions and data collection: AMI was defined as typical chest pain lasting for more than 30 minutes with ST-segment elevation of > 1 mm in 2 consecutive precordial or inferior leads. Procedural success was defined as successful primary PCI deployment at the desired position with a residual stenosis of < 20% followed by TIMI grade 3 flow in the IRA. Multivessel disease was defined by stenoses of > 50% in 2 or more major epicardial coronary arteries. Unsuccessful reperfusion was defined as final TIMI flow of 2 or less in the IRA after primary PCI. Recurrent ischemia was defined as recurrent chest pain lasting longer than 20 minutes with a new ischemic electrocardiographic change. If these findings were associated with at least a 50% increase in the previous CK-MB trough, reinfarction was diagnosed. Myocardial blush grade and thrombus score were defined as described previously. 16, 17) Complete heart block was defined as complete interruption of atrioventricular conduction with complete P wave and QRS dissociation and the existence of junctional or ventricular escape rhythm with a heart rate of less than 60 or 40 beats/min, respectively. New onset of CHB which developed during the interventional procedure was further divided into transient CHB (defined as complete recovery to sinus rhythm after the procedure) and persistent CHB (defined as persistently present after the procedure). Additionally, both transient and complete CHB caused unstable hemodynamics which required emergency management, including fluid supply, atropine and vasopressor agent use, or temporary pacemaker implantation in the right ventricle.
Detailed in-hospital and follow-up data, including age, sex, coronary risk factors, Killip score on admission, preinfarction angina, white blood cell counts, biochemistry studies, serum level of hs-CRP, angiographic findings, and number of diseased vessels were obtained. These data were collected prospectively and entered into a computerized database. Anticoagulant utilization: Before clopidogrel was available in our country, ticlopidine was given (500 mg preoperative loading dose then 250 mg/day) for at least 4 weeks to the patients who underwent primary coronary stenting. After clopidogrel became available in Taiwan, clopidogrel was given (300 mg preoperative loading dose then 75 mg/day) for at least 4 weeks to the patients who underwent primary stenting. Each patient was given chewable aspirin (324 mg) and a 5000 U bolus of intravenous heparin in the emergency room. Before primary PCI, the patient received intracoronary heparin (5000 U to 10000 U) to achieve an activated clotting time (ACT) ≥ 320 seconds. Heparin was continuously given to those patients who had received primary balloon angioplasty (for 48 hours) only, to those who had final TIMI flow ≤ 2 in the infarct-related artery, and to those who had received IABP support. Aspirin (100 mg/day orally) was given to each patient indefinitely.
Tirofiban therapy (loading dosage of 20 µg/kg of body weight) was administered to patients upon presentation in the emergency room, followed by a maintenance infusion of 0.15 µg/kg/min for 18 to 24 hours at the beginning of the study. However, tirofiban therapy was subsequently withheld because it was found not to provide any additional benefit to AMI patients who underwent primary PCI. 15 ) Therefore, only 20 (17.7%) patients received tirofiban therapy. Statistical analysis: The data are expressed as the mean ± SD. Continuous variables were compared using the Wilcoxon rank-sum test. Categorical variables were compared using the chi-square or Fischer exact test. Stepwise logistic regression analysis was used to determine the independent predictors of prevention for combined incidence of new onset of CHB and restoration of sinus rhythm from CHB. SAS statistical software for Windows version 8.2 (SAS Institute, Cary, NC) was used for the statistical analyses. A value of P < 0.05 was considered statistically significant.
RESULTS
Baseline characteristics, angiographic results, and 30-day clinical outcomes:
Tables I and II list the relevant patient characteristics, angiographic findings, procedural success rates, and clinical outcomes of both groups. No significant differences in age, gender, coronary artery disease risk factors, previous MI, cardiogenic shock, or CHB upon presentation were identified between the 2 groups. However, use of intra-aortic balloon pump support was significantly higher in group 2 than in group 1. The combined incidence of new onset of CHB following the interventional procedure was significantly higher in group 2 than in group 1 patients. In addition, the recovery time from CHB to first-degree heart block or normal sinus rhythm was remarkably longer in group 2 than in group 1. Furthermore, the peak level of creatine kinase (CK-MB) was significantly higher Vol 48 No 1 in group 2 than in group 1, and the incidence of using pre-PCI adjunctive tirofiban therapy was significantly higher in group 2 than in group 1 patients.
There were no significant differences with regard to multivessel disease, pre-TIMI flow, initial diameter stenosis, lesion length, initial, final minimal lumen, or reference lumen diameter, stent implantation, incidence of requirement for predilatation, maximal pressure for final dilatation, number of stents used, or mean of stent length between the groups. However, the final TIMI-3 flow and the myocardial blush grades were significantly higher in group 1 than in group 2, whereas the incidences of distal embolization and a post-PCI residual thrombus score ≥ 3 were significantly higher in group 2 than in group 1. Additionally, the incidence of postprocedural heparinization was significantly higher in group 2 than in group 1. The combined 30-day major adverse cardiac event rate was also significantly higher in group 2 than in group 1. The duration of hospitalization in group 2 was significantly longer than that in group 1. Independent predictors of preventing complete heart block: Multiple stepwise analyses assessed the relationships between enrollment factors (Tables I and II) and combined incidence of new onset of CHB following PCI, and the associa- tions between these enrollment factors and recovery time from CHB. Analytical results demonstrated that the PercuSurge device was the only independent predictor of preventing the combined incidence of onset of CHB during the procedure [odds ratio (OR) = 6.7, 95% confidence interval (CI): 3.3 -18.2; P < 0.0001)]. This mechanical device (OR = 8.7, 95% CI: 3.1 -23.7; P < 0.0001) along with a final TIMI-3 flow (OR = 5.3, 95% CI: 1.8 -16.7; P = 0.0017) and final myocardial blush ≥ 2 grades (OR = 7.3, 95% CI: 2.64 -31.8; P = 0.0001) was independently associated with reducing the recovery time from CHB. 
DISCUSSION
The principle finding of this study is that the PercuSurge distal balloon protection device significantly and independently prevented combined new onset of CHB following wiring or balloon dilation of the obstructive lesion. Recent studies 14, [18] [19] [20] have demonstrated that large IRAs usually contain HBTF, a component of red, fibrin-rich clots, 14, 20, 21) platelet-rich thrombi, 21) and lipid pool-like contents. 19) During wiring, small thrombi are dislodged into the microvasculature. Following balloon dilatation or stent implantation, large thrombi, plaque, and lipid pool-like cholesterol are crushed, subsequently embolizing the distal vasculature, 12, 14, [18] [19] [20] which in turn causes slow flow or no-reflow phenomenon of epicardial vessels and microvasculature. Likewise, the atheroma-related embolization can plug up the atrioventricular nodal artery and cause further ischemia in this vessel. These could, at least in part, explain why primary PCI alone significantly increased the rate of developing CAVB during the procedure in group 2 patients. Recent studies have shown that the PercuSurge distal balloon protection device is a clinically useful tool for preventing embolization in microvasculature and no reflow during primary PCI or saphenous vein intervention. 12, 13) Another recent study has also demonstrated that a distal protection device is effective at preventing distal embolization during primary PCI. 22) In this study, the combined use of primary PCI and the PercuSurge device significantly reduced residual intracoronary thrombus scores, prevented distal thrombus-or atheroma-related embolization, and independently increased final TIMI-3 flow and microvascular reperfusion. Our findings corroborated those obtained by these recent studies 12, 13) and further extended the finding that the PercuSurge distal balloon protection device can prevent the occurrence of CHB during the procedure. Taking these into consideration, we suggest that successful reperfusion by combined utilization of a PercuSurge distal protection balloon and Export Suction Catheter to remove the atherothrombi plays a crucial role in attenuation of the combined incidence of new onset of CHB.
Another important finding is that utilizing the PercuSurge distal balloon protection device significantly and independently reduced the recovery time of CHB in our patients. Although the mechanisms of this finding can not be easily explained, we speculate that it could be essentially due to a successful reperfusion of epicardial flow and microvasculature of IRA after primary PCI which can promptly relieve ischemia of the atrionodular artery and, in turn, quickly restore atrioventricular nodular artery function (Figure) . This can explain why the final myocardial blush grade was an independent predictor of early recovery from CHB. Previous studies have postulated that CHB following AMI is related to Bezold-Jarisch reflex, ischemia, and local accumulations of chemical media-tors. 4, 23) Additionally, previous studies have also demonstrated that CHB can completely recover in a majority of patients following AMI. [1] [2] [3] [4] This could be due to spontaneous recanalization of the IRA or the development of new intercoronary collateral circulation which, in turn relieves the ischemia of the atrionodular artery. Thus, this study extended the findings of these studies, [1] [2] [3] [4] 23) further supporting the concept that ischemia 24) is the primary reason for CHB in the clinical setting of AMI.
Preprocedural adjunctive tirofiban therapy did not increase successful reperfusion rates or reduce the combined incidence of new onset of CHB during primary PCI. Furthermore, this pharmacological therapy also did not reduce the recovery time from CHB in this study. We suggest that tirofiban therapy cannot lyse the macro-thrombi and lipid pool-like contents or prevent distal embolization of thrombi and cholesterol debris, which remain as causes of slow-flow or no-reflow phenomena during primary PCI. This suggestion is supported by the Figure. A: Total occlusion from proximal right coronary artery (RCA); wide QRS pattern of electrocardiography (ECG) tracing is shown by ECG monitor on the bottom of panels A, B and C due to temporary pacemaker pacing. B: PercuSurge distal protection balloon was inflated (black arrowhead); marked intracoronary thrombus formation was shown by contrast media (black arrows). C: While the stent was deployed (black arrows), the PercuSurge distal protection balloon was being inflated (black arrowhead). D: Following successful stent implantation, the moderate diffuse atherosclerosis of distal RCA was noted; successful reperfusion of microvasculature (grade 3 myocardial blush) (black arrowheads) was identified.
